* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download What is an optimal dosage regimen - Physiologie et Thérapeutique
Survey
Document related concepts
Pharmacognosy wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Environmental impact of pharmaceuticals and personal care products wikipedia , lookup
Environmental persistent pharmaceutical pollutant wikipedia , lookup
National Institute for Health and Care Excellence wikipedia , lookup
Discovery and development of cephalosporins wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Antibiotics wikipedia , lookup
Transcript
How to establish a dosage regimen for a sustainable use of antibiotics in veterinary medicine P.L. Toutain National Veterinary School ; Toulouse, France The workshop • A general presentation by PLT • Three questions to be discussed in subgroups animated by team leaders: – Peter Lees: • the needs of innovation – Ted Whittem: • PKPD, pop kinetics & MCS in antibiotic development – Marilyn Martinez: • regulatory hurdles to antibiotic development "The design of appropriate dosage regimens may be the single most important contribution of clinical pharmacology to the resistance problem" Schentag et al. Annals of Pharmacotherapy, 30: 1029-1031 EMEA "Points to consider" July 2000 • Inadequate dosing of antibiotics is probably an important reason for misuse and subsequent risk of resistance • A recommendation on proper dosing regimens for different infections would be an important part of comprehensive strategy • The possibility to produce such a dose recommendation based on pharmacokinetic and pharmacodynamic considerations will be further investigated in one of the CPMP working parties... Medical consequences of AMR The antibiotic ecosystem: one world, one health Treatment & prophylaxis Veterinary medicine Human medicine Community Hospital Animal feed additives Agriculture Plant protection Environment Industry The priorities of a sustainable veterinary antimicrobial therapy is related to public health issues, not to animal health issues The three (not 2) endpoints to consider in veterinary medicine • Efficacy in animal • No promotion of resistance in animal (target pathogen) • No promotion of resistance in man But of what resistance are we speaking? Prevent emergence of resistance: but of what resistance? Target pathogens Drug efficacy in animal: A vet issue Possible overuse of antibiotics Animal issue Zoonotics Drug efficacy in man Natural eradication Individual issue Commensal flora Resistance gene reservoir Global ecological problem Risk for permanent colonisation Population issue What are the animal’s ecosystems potentially able to raise public health concerns in terms of antimicrobial resistance? The critical animal ecosystem's in terms of emergence and spreading of resistance • Open and large ecosystems – Digestive tract – Skin • Open but small ecosystem – Respiratory tract • Closed and small ecosystem – Mammary gland Bacterial load exposed to antibiotics during a treatment Test tube 1µg Infected Lungs 1 mg Digestive tract 2-3Kg Food chain Manure waste Several tons Soil, plant…. Biophases & antimicrobial resistance AB: oral route Proximal G.I.T 1-F% Distal Gut flora •Zoonotic (salmonella, campylobacter •commensal ( enterococcus) Food chain Environmental exposure Blood Target biophase Bug of vet interest Résistance = lack of efficacy Résistance = public health concern Bioavailability of oral tetracyclins • Chlortetracycline: – Chickens:1% – Pigs Fasted or fed: 18 to 19% – Turkeys:6% • Doxycycline: – Chickens:41.3% . – Pigs :23% • Oxytetracycline: – Pigs:4.8% – Piglets, weaned, 10 weeks of age: by drench: 9%;in medicated feed for 3 days: 3.7% . – Turkeys: Fasted: 47.6% ;. Fed: 9.4% • Tetracycline: – Pigs fasted:23% . Biophases & antibiorésistance Gastrointestinal tract Proximal Gut flora •Zoonotic (salmonella, campylobacter •commensal ( enterococcus) Intestinal secretion Bile Systemic Administration Distal Quinolones Macrolides Tétracyclines Food chain Environment Blood Biophase Target pathogen Résistance =public health issue Résistance = lack of efficacy Genotypic evaluation of ampicillin resistance: copy of blaTEM genes per gram of feces 1 E+10 oral route fed copies/g of feces 1 E+9 1 E+8 oral route fasted 1 E+7 intramuscular route 1 E+6 control group 1 E+5 1 E+4 0 1 2 3 days 4 5 6 7 A significant effect of route of administration on blaTEM fecal elimination (p<0.001). Marbofloxacin impact on E. coli in pig intestinal flora (From P. sanders, Anses, Fougères) IV • • • • IM 3 days Before treatment : E. coli R (0.01 to 0.1%) After IV. :Decrease of total E coli , slight increase of E. coli R (4 to 8 %) Back to initial level After repeated IM (3d) : Decrease below LoD E. coli (2 days), fast growth (~ 3 106 ufc/g 1 d). E. coli R followed to a slow decrease back to initial level after 12 18 days • Performance-enhancing antibiotics (old antibiotics) – chlortetracycline, sulfamethazine, and penicillin (known as ASP250)] • phylogenetic, metagenomic, and quantitative PCR-based approaches to address the impact of antibiotics on the swine gut microbiota • It was shown that antibiotic resistance genes increased in abundance and diversity in the medicated swine microbiome despite a high background of resistance genes in nonmedicated swine. • Some enriched genes, demonstrated the potential for indirect selection of resistance to classes of antibiotics not fed. The three (not 2) endpoints to consider in veterinary medicine • Efficacy in animal • No promotion of resistance in animal (target pathogen) • No promotion of resistance in man??????? Innovation: PK selectivity of antibiotics Proximal Distal 1-F=90% Oral Efflux F=10% IM Gut flora •Zoonotic (salmonella, campylobacter •commensal ( enterococcus) Food chain Quinolones, macrolides environment Blood Kidney Biophase Animal health Résistance = public health concern - 22 Question 1: Peter Lees • Do we need new antibiotics to fit our expectation in terms of public health or rather to encourage the use of old antibiotics and the promotion of generics The right dosage regimen What are the elements of a dosage regimen • The dose & The dosing interval • The treatment duration –When to start –When to finish How to find and to confirm a dose (dosage regimen) • Dose titration – Animal infectious model • PK/PD Dose titration Dose Response clinical Black box PK/PD PK Dose Body PD pathogen Response An exposure variable scaled by MIC Nice buiatric 2006-27 The dose-titration ECVPT Toulouse 2009 28 Only the parallel design for antibiotics: Statistical model Response NS • The null hypothesis * * – placebo = D1 = D2 = D3 • The statistical linear model – Yj = wj + j Selected dose Placebo1 2 3 Dose • Conclusion – D3 = D2 > D1 > Placebo The parallel design • Advantages – easy to execute – total study lasts over one period – approved by Authorities • Disadvantages – "local information" (response at a given dose does not provide any information about another dose) – no information about the distribution of the individual patient's dose response. The dose-titration: experimental infectious model • Severe • not representative of the real world – Prophylaxis vs. metaphylaxis vs. curative • power of the design generally low for large species • influence of the endpoints Antibiotic dosage regimen based on PKPD and population PK concepts Measuring exposure and response in PK/PD trial It has been developed surrogates indices (predictors) of antibiotic efficacy taking into account MIC (PD) and exposure antibiotic metrics (PK) Practically, 3 indices cover all situations: •AUC/MIC •Time>MIC • Cmax/MIC PK/PD predictors of efficacy • Cmax/MIC : aminoglycosides • AUC/MIC : quinolones, tetracyclines, azithromycins, • T>MIC : penicillins, cephalosporins, macrolides, Cmax Concentrations Cmax/MIC AUIC = AUC MIC MIC T>CMI 24h Time Nice buiatric 2006-35 Appropriate PK/PD indices for the different antibiotics according to their bactericidal properties Bactericidal pattern Type I Concentration dependant & persistent effect Type II Time-dependent and no persistent effect Type III Time-dependent and dosedependent persistent effect Antibiotics Therapeutic goal PKPD indices Aminoglycosides Fluoroquinolones To optimize plasma concentrations Cmax/MIC 24h-AUC/MIC Penicillins Céphalosporins To optimize duration of exposure T>MIC Macrolides Tétracyclines To optimize amount (doses) 24h-AUC/MIC What is the appropriate magnitude of PK/PD indices to guarantee efficacy i.e. how establish PK/PD breakpoint values: 1. To optimize efficacy 2. To minimize resistance towards the target pathogen Breakpoint values in veterinary medicine • Starting values – From human medicine – From in vitro/ex vivo (tissue cage) experiments • In vivo experimental determination Nice buiatric 2006-38 First step of the PKPD approach • To establish experimentaly the numerical value of the PKPD surrogate that garantee a Probability of cure (POC) or any other relevant endpoint (bacteriokogical cure…) – E. g what is the numerical value of the AUC/MIC for a new quinolone to obtain more than 90% of clinical success in pigs treated metaphylactically for a lung condition? Nice buiatric 2006-39 A working example Your development project • You are developing a new antibiotic in pigs (e.g. a quinolone) to treat respiratory conditions and you wish to use this drug in for metaphylaxis (control) • collective treatment & oral route Questions for the developers • What is the optimal dosage regimen for this new quinolone for metaphylaxis ings • To answer this question, you have, first, to define what is an “optimal dosage regimen” MonteCarlo-Orlando06 42 Step 1: Define what is an optimal dosage regimen What is an optimal dosage regimen ? 1. Efficacy : – it is expected to cure at least 90% of pigs – “Probability of cure” = POC = 0.90 • We know that the appropriate PK/PD index for that drug (quinolone) is AUC/MIC • We have only to determine (or to assume) its optimal breakpoint value for this new quinolone What is an optimal dosage regimen ? 2. Emergence of resistance – The dosage regimen should avoid the mutant selection window (MSW) in at least 90% of pigs Plasma concentrations The selection window hypothesis Mutant prevention concentration (MPC) (to inhibit growth of the least susceptible, single step mutant) Mutant Selection window All bacteria inhibited MIC Selective concentration (SC) to block wild-type bacteria Growth of only the most resistant subpopulation Growth of all bacteria Two endpoints for an optimal dosing regimen 1. Probability of “cure” = POC = 0.90 2. Time out of the MSW should be higher than 12h (50% of the dosing interval) in 90% of pigs Step 2: Determination of the AUC/MIC clinical breakpoint value for the new quinolone in pigs Determination of the PK/PD clinical breakpoint value • Dose titration in field trials : – 4 groups of 10 animals – Blood samples were obtained – MIC of the pathogen is known Possible to establish the relationship between AUC/MIC and the clinical success MonteCarlo-Orlando06 49 AUC/MIC vs. POC: Metaphylaxis 1 0.9 0.8 POC POC 0.7 Data points were derived by forming ranges with 6 groups of 5 individual AUC/MICs and calculating mean probability of cure 0.6 0.5 0.4 0.3 0.2 10 Control pigs (no drug) 0.1 0 0 50 100 AUC/MIC AUC/MIC 150 200 Probability of cure (POC) • Logistic regression was used to link measures of drug exposure to the probability of a clinical success POC Dependent variable 1 1 e a bf AUC MIC Placebo effect sensitivity Independent variable 2 parameters: a (placebo effect) & b (slope of the exposure-effect curve) Metaphylaxis (collective treatment) 1.2 1 POC 0.8 0.6 0.4 0.2 0 0 50 100 150 AUC/MIC 1 1 e 0.4050.0325 AUC MIC 200 Conclusion step 2 Metaphylaxis Placebo effect 40% Breakpoint value of AUC/MIC to achieve a POC=0.9 80h Step 3 What is the dose to be administrated to guarantee that 90% of the pig population will actually achieve an AUC/MIC of 80 for an empirical (MIC unknown) Determination of a dose for a quinolone Breakpoint value e.g. 80h PD AUC Clearance (per hours) MIC MIC BP Dose fu F % Bioavailability Free fraction Solving the structural model to compute the dose for my new quinolone • With point estimates – (mean, median, best-guess value…) • With range estimates – Typically calculate 2 scenarios: the best case & the worst case (e.g. MIC90) – Can show the range of outcomes • By Monte Carlo Simulations – Based on probability distribution – Give the probability of outcomes Computation of the dose with point estimates (mean clearance and F%, MIC90) BP: 80 MIC50=1µg/mL 9mL/Kg/h AUC Clearance (per hours) MIC MIC BP Dose F% Dose: 1.44mg/kg Bioavailability=50% Computation of the dose with point estimates (worst case scenario for clearance and F%, MIC90) BP: 80 MIC90=2µg/mL 15mL/Kg/h AUC Clearance (per hours) MIC MIC BP Dose F% Bioavailability= 30% Dose: 8.0 (vs. 1.44) mg/kg MonteCarlo-Orlando06 58 Computation of the dose using Monte Carlo simulation (Point estimates are replaced by distributions) Log normal distribution: 9±2.07 mL/Kg/h Observed distribution BP metaphylaxis Clearance 80 MIC Dose F% Dose to POC=0.9 MonteCarlo-Orlando06 Uniform distribution: 0.3-0.70 59 • An add-in design to help Excel spreadsheet modelers perform Monte Carlo simulations • Others features – Search optimal solution (e.g. dose) by finding the best combination of decision variables for the best possible results Metaphylaxis: dose to achieve a POC of 90% i.e. an AUC/MIC of 80 (empirical antibiotherapy) Dose distribution MonteCarlo-Orlando06 61 Computation of the dose: metaphylaxis (dose=2mg/kg from the dose titration) PK/PD Model Dose (mg/kg) Mean 1.44 Worst case scenario 8.00 Monte Carlo 3.803 (empirical antibiotherapy) Sensitivity analysis • Analyze the contribution of the different variables to the final result (predicted dose) • Allow to detect the most important drivers of the model Sensitivity analysis Metaphylaxis, empirical antibiotherapy Contribution of the MIC distribution MonteCarlo-Orlando06 64 The second criteria to determine the optimal dose: the MSW & MPC Kinetic disposition of the new quinolone for the selected metaphylactic dose (3.8 mg/kg) (monocompartmental model, oral route) Log normal distribution: 9±2.07 mL/kg/h F% Uniform distribution: 0.3-0.70 Slope=Cl/Vc=0.09 per h (T1/2=7.7h) concentrations (µg/mL) concentrations 8 MPC 7 6 5 MIC 4 Série1 3 2 MSW 1 0 0 5 10 15 Time (min) 20 25 30 Computation of the dose (mg/kg): for given target attainment rates (TAR) for efficacy and to prevent selection of mutants Monte Carlo curative Efficacy 3.8 To guarantee T>MPC in 90% of pigs for 50% the dosage interval 5.9 Question 2 Ted Whittem • What is the place of PK/PD, population kinetic and Monte Carlo Simulations in the rational development of a new antibiotic: the pro & cons, limits…. 4-The right duration When to start a treatment? The different usages of antibiotics Disease health Antibiotic consumption Therapy Metaphylaxis (Control) Pathogen load Prophylaxis (prévention) Growth promotion Only a risk factor High Small No NA MICs estimated with different inoculmum densities, relative to that MIC at 2x105 Ciprofloxacin Gentamicin Linezolid Oxacillin Daptomycin Vancomycin The inoculum effect and Very Early Treatment (VET) • Efficacious dosage regimen is different when the pathogen load is large, low or null • Treatment should start as early as possible What was demonstrated • For a same dose of marbofloxacin, early treatments (10 hours after the infection) were associated to – more frequent clinical cure – more frequent bacteriological cure – less frequent selection of resistant bacteria than late treatments (32 hours after the infection) Early administrations were more favourable than late administrations Metaphylaxis and Very Early Treatment (VET) • I suggest to replace metaphylaxis by VET because metaphylaxis convey negative values – Confusion with mass treatment, – Confusion with prophylaxis When to finish a treatment? • ASAP • Should be determined in clinics • Should be when clinical cure is actually achieved • Should not be a hidden prophylactic treatment for a possible next infectious episode Question 3 Marilyn Martinez • What are the hurdles to the development of a new antibiotic or to the revisit an old antibiotic – Possibility or not to have several dosage regimen (curative vs. control VS prophylaxis) – Protection of innovation – Regulatory climate – Acceptance or not of PK/PD, Pop, MCS…. – Validity of susceptibility testing and development of appropriate breakpoints – Hypothesis to test for clinical trial: non inferiority or superiority? – …. Conclusion • You have 25 minutes to discuss theses 3 questions